Aragen Life Sciences Limited has proposed an initial public offering of equity shares, comprising a fresh issue aggregating to ₹800 crore and an offer for sale of up to 27,329,192 equity shares by the selling shareholders.
Cyril Amarchand Mangaldas is advising Aragen Life Sciences on this IPO.
The transaction team is being led by Yash J. Ashar (Senior Partner) and Tanvi Kini (Partner), with support from Surya Rajkumar (Senior Associate), Associates Tejaswi Sade, Mohammed Khadri, Maria Palamattom and Akshita Dhawan.
TT&A is advising selling shareholders Leo Investment Holdings Pte. Ltd. and Quadria Capital India Fund III (both Quadria affiliate entities) on this IPO.
The transaction is being led by Abhinav Kumar (Partner) and Indira Satish (Senior Associate).
Trilegal is advising the Book Running Lead Managers, Axis Capital, Citigroup Global, Goldman Sachs and JM Financial, on this IPO.
The transaction is being led by Bhakta Patnaik (Partner) and Albin Thomas (Partner), and comprises Bhargavi Mahajan (Counsel), Associates Janhavi Shah, Snehal Kaushal, Tushar Chitlangia, Mohak Agarwal, and Harshali Srivastava.
Aragen Life Sciences is the largest CRDMO among the assessed Indian peers in terms of number of solutions offered across the drug development value chain as of March 31, 2026, and one of India’s leading CRDMO platforms offering solutions across the drug development lifecycle for both small molecules and biologics as per the F&S Report.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.